Cochlear Implants
May 15, 2025
Glucotrack Secures Ethical Approval for Extended Clinical Trial of Continuous Blood Glucose Monitor; GE HealthCare Announces FDA Approval for Pediatric Use of Optison and Launches New Ultra-premium 1.5T MRI System; Envoy Medical Advances to Final Stage Following Clinical Milestone; SeaStar Medical Hits Interim Enrollment Goal in NEUTRALIZE-AKI Trial; BD Unveils New Cell Analyzer Integrating Spectral and Real-Time Imaging Innovations
Glucotrack Announced Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor On May 13, 2025, Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it received ethical app...
Read More...
Mar 20, 2025
Illuccix Receives Dutch Approval for PSMA-PET Imaging in Prostate Cancer; FDA Approves Valcare Medical’s Early Feasibility Study for Novel Amend™ Trans-Septal System; RevBio Launches Pivotal Clinical Trial in Europe for Dental Implant Stabilization; Insulet’s RADIANT Trial Highlights Improved Glycemic Outcomes with Omnipod® 5 Following Direct Transition; Envoy Medical Raises $10 Million to Drive Clinical Progress on Next-Gen Hearing Device; Vave Health Unveils World’s First Wireless Whole-Body Ultrasound with Single PZT Transducer
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in the Netherlands On March 18, 2025, Telix announced that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), received marketing authorization from the Medicines Evaluation Board (MEB) in t...
Read More...
Apr 25, 2024
iVEAcare’s $27.5 Million Series A Funding; AI Medical Service Joint Research Agreement with Mahidol University; CERENOVUS Launched Catheter; Cochlear FDA Clearance for The Osia System; Immunovia Announced Positive Results From The Model-Development Study; Hyalex Orthopaedics First Patients Treatment
iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024, iVEAcare, announced the closure of a $27.5 million Series A financing. The financing was led by Vensana Capital, which was joined by Treo Ventures, Hatteras Venture Partners, and an undisclosed strategic partner. i...
Read More...
Jan 10, 2024
Ears to the Future: Evaluating Key Advancements and Trends Driving the Audiology Devices Market Growth
Audiology Devices have witnessed an unprecedented surge in demand in recent years. One of the primary drivers is the escalating prevalence of hearing impairments globally, attributed to various factors such as an aging population and increased exposure to environmental noise. As per the World Health Organization (W...
Read More...
Nov 03, 2022
AngioDynamics’s AlphaVac F18 PE System; Pfizer’s RSVpreF/PF-06928316 Trial; Intelligent Ultrasound’s ScanNav Anatomy PNB; FDA Approves the Cochlear Nucleus 8 Sound Processor; Ameda’s Pearl Breast Pump; J&J to Buy Abiomed; Thermo Fisher Scientific to Acquire The Binding Site Group
AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism On October 31, 2022, AngioDynamics, a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer...
Read More...
Sep 28, 2022
Evaluating the Growing Role of Devices in the Rehabilitation of Hearing Impairment
Hearing loss is a growing public health concern, and the number of cases is rising globally at a significant pace. As per the WHO, more than 1.5 billion people (nearly 20% of the global population) live with hearing loss, and 430 million of them have disabling hearing loss. According to the NIDCD, in the United Sta...
Read More...
Oct 13, 2021
Analysing the Treatment Approaches in the Hearing Loss Market and Key Companies in the Domain
Hearing Loss is a severe condition that has a multifaceted impact on the individual’s growth and development. It can lead to isolation and loneliness and can also significantly reduce the quality of life. As per the WHO, nearly 430 million people (representing over 5% of the world’s population) require rehabilitati...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
